|
Monday, March 9 — 1:00 PM — CC 302
Click on the blue numbers in parentheses to display abstracts.
Click the  button next to any title to add to Itinerary Planner...
Section D - HEMATOPATHOLOGY
Chaired by: Megan Lim and April Chiu
| Time | Title and Authors | Itinerary
Planner |
| 1:00 |
MicroRNA Expression in DLBCL: Identification of Unique miRNAs Signatures Related to Clinical Outcome Prediction in R-CHOP Treated Patients
(1262)
S Montes-Moreno, N Martinez, A Saez, C Montalban, MH Rodriguez, B Sanchez-Espiridion, SM Rodriguez Pinilla, GB Lemarbre, WM Rehrauer, M Waknitz, KH Young, MA Piris - Spanish National Cancer Center, CNIO, Madrid, Spain; UW Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI
|  Add |
| 1:15 |
High Proliferation Rate in Mantle Cell Lymphoma Is Associated with p53 Mutations and Blastoid Morphology, but Not with 3'UTR Deficient Cyclin D1 mRNA or High Total Cyclin D1 mRNA Levels
(1298)
J Slotta-Huspenina, I Koch, L de Leval, G Keller, K Bink, M Kremer, M Raffeld, F Fend, L Quintanilla-Martinez - Institute of Pathology, Technical University, Munich, Germany; Institute of Pathology, Helmholtz Center Munich, Munich, Germany; 3 Institute of Pathology, University of Tuebingen, Tuebingen, Germany; University of Leige, Liege, Belgium; National Cancer Institute, Bethesda
| Add |
| 1:30 |
Plasmablastic Lymphomas Are Genetically Characterized by Frequent MYC Translocations
(1160)
O Balague, S Valera, A Martinez, L Colomo, J Delabie, A Macolscy, E Campo - Hospital Clinic, University of Barcelona, Barcelona, Spain; Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; Semmelweis University, Budapest, Hungary
| Add |
| 1:45 |
IgM Plasma Cell Myeloma: Clinicopathologic Characterization of a Rare Entity
(1168)
N Cetin, I Bansal, W Bellamy, M Santra, B Barlogie, RB Lorsbach - University of Arkansas for Medical Sciences, Little Rock, AR; Myeloma Institute of Research and Technology, Little Rock, AR
| Add |
| 2:00 |
High-Risk Genetic Prognostic Factors Including 17p(p53) Deletion, 1q21 Gains and 1p21 Loss Do Not Affect Bortezomib Therapy Responsiveness and Survival of Relapsed/Refractory Myeloma Patients
(1275)
C Qi, Y Trieu, D Reece, H Chang - University Health Network and University of Toronto, Toronto, Canada
| Add |
| 2:15 |
Expression of Intergrin Beta 7 Identify a "High Risk Group" among Multiple Myeloma Patients Treated with High Dose Chemotherapy Followed by Autologus Stem Cell Transplantation
(1253)
A Mansoor, SMT Rad, A Klimowicz, A Magliocco, X Jiang, D Stewart, N Bahlis - University of Calgary/CLS, Calgary, AB, Canada; Tom Baker Cancer Ctr., Calgary, AB, Canada
| Add |
| 2:30 |
An Orally Available Syk Tyrosine Kinase Inhibitor Induces Apoptosis in Peripheral T-Cell Lymphomas Overexpressing Activated Syk
(1317)
R Wilcox, D Sun, ED Remstein, A Dogan, S Ansell, AL Feldman - Mayo Clinic, Rochester, MN
| Add |
| 2:45 |
IRF4 Translocations Are Specific for Cutaneous Anaplastic Large Cell Lymphoma in Skin Biopsies Involved by T-Cell Lymphoproliferative Disorders
(1308)
D Wada, ME Law, A de Souza, R Weenig, N Comfere, WR Macon, LA Erickson, A Dogan, AL Feldman - Mayo Clinic, Rochester, MN
| Add |
| 3:00 |
RECESS, EXHIBITS, POSTER SESSION II
| |
| 4:30 |
NATHAN KAUFMAN TIMELY TOPICS LECTURE
Todd R. Golub, M.D.
Molecular Classification of Tumors
Hynes Convention Center Auditorium
| Add |
|
|
